Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 14

1.

The effectiveness and safety of amisulpride in Chinese patients with schizophrenia: An 8-week, prospective, open-label, multicenter, single-arm study.

Liang Y, Cao C, Zhu C, Wang C, Zhang C, Dong F, Yang F, Deng H, Yu J, Tang J, Su L, Xin L, Hong L, Gao M, Tang M, Xie S, Lu S, Liu T, Xu X, Wang X, Li X, Wang X, Li Y, Zhang Y, Chen Z, Yu X.

Asia Pac Psychiatry. 2016 Sep;8(3):241-4. doi: 10.1111/appy.12238. Epub 2016 Mar 28.

2.

Efficacy of amisulpride and olanzapine for negative symptoms and cognitive impairments: An open-label clinical study.

Kumar S, Chaudhury S.

Ind Psychiatry J. 2014 Jan;23(1):27-35. doi: 10.4103/0972-6748.144953.

3.

Metabolic, endocrinologic and cardiac effects of amisulpride: a 24-week follow-up study.

Kotan Z, Ertepe B, Akkaya C, Sarandol E, Ozkaya G, Kirli S.

Ther Adv Psychopharmacol. 2011 Dec;1(6):189-96. doi: 10.1177/2045125311426896.

4.

Psychiatrists' perceptions of the clinical importance, assessment and management of patient functioning in schizophrenia in Europe, the Middle East and Africa.

Gorwood P, Burns T, Juckel G, Rossi A, San L, Hargarter L, Schreiner A; Europe, Middle East and Africa functioning group.

Ann Gen Psychiatry. 2013 Mar 26;12(1):8. doi: 10.1186/1744-859X-12-8.

5.

Safety and tolerability of antipsychotics: focus on amisulpride.

Juruena MF, de Sena EP, de Oliveira IR.

Drug Healthc Patient Saf. 2010;2:205-11. doi: 10.2147/DHPS.S6226. Epub 2010 Oct 1.

6.

Olanzapine versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654. doi: 10.1002/14651858.CD006654.pub2. Review.

7.

Amisulpride versus other atypical antipsychotics for schizophrenia.

Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Silveira da Mota Neto JI, Kissling W, Leucht S.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD006624. doi: 10.1002/14651858.CD006624.pub2. Review.

8.

Update on the management of symptoms in schizophrenia: focus on amisulpride.

Mortimer AM.

Neuropsychiatr Dis Treat. 2009;5:267-77. Epub 2009 May 20.

9.

Social functioning and quality of life as measures of effectiveness in the treatment of schizophrenia.

Kwon JS, Choi JS.

World Psychiatry. 2009 Feb;8(1):35-6. No abstract available.

10.
11.

The use of amisulpride in the treatment of acute psychosis.

Nuss P, Hummer M, Tessier C.

Ther Clin Risk Manag. 2007 Mar;3(1):3-11.

12.

Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features.

Rabinowitz J, Levine SZ, Barkai O, Davidov O.

Schizophr Bull. 2009 Jul;35(4):775-88. doi: 10.1093/schbul/sbn005. Epub 2008 Feb 26.

13.

Methodological issues in current antipsychotic drug trials.

Leucht S, Heres S, Hamann J, Kane JM.

Schizophr Bull. 2008 Mar;34(2):275-85. doi: 10.1093/schbul/sbm159. Epub 2008 Jan 29. Review.

14.

The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study.

Herrera-Estrella M, Apiquian R, Fresan A, Sanchez-Torres I.

BMC Psychiatry. 2005 May 3;5:22.

Supplemental Content

Support Center